We love to hear from our listeners. Send us a message.
Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse. Increased deal activity with Chinese biopharmaceutical companies is injecting new risk into traditional development models in the West, despite an uncertain policy environment in the U.S. vis-à-vis China. Will faster trial starts, cheaper asset upfronts, and a growing talent base slingshot Shanghai's biotech hub into an innovation destination on par with Boston and San Francisco?
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
